Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Postsynaptic neurotoxins, commonly referred to as alpha-neurotoxins, are a class of snake venom proteins that bind with high affinity to postsynaptic nicotinic acetylcholine receptors on skeletal muscle at the neuromuscular junction, competitively inhibiting acetylcholine binding[4][5][6][7]. This blockade disrupts normal synaptic transmission, leading to paralysis, which can be fatal if respiratory muscles are affected. Alpha-neurotoxins fall into the 'three-finger toxin' (3FTx) protein superfamily and are further classified into short-chain and long-chain subtypes based on their amino acid length and disulfide bond configuration[4]. They are used extensively as probes in neuroscience to study the structure and function of acetylcholine receptors, but are not themselves therapeutic targets—rather, they are the active agents in venom toxicity for which antivenoms are developed.
Competitive antagonism of nicotinic acetylcholine receptors (nAChRs) at postsynaptic membranes, blocking acetylcholine binding and preventing synaptic transmission[4][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-neurotoxin (null).